Supplementary Table 2 from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
Ida Aronchik(Revolution Medicines (United States)), Anne B. Jefferson, Stephen E. Basham(Therapeutics Clinical Research), Mika Lindvall, Catherine A. Luu(Joint BioEnergy Institute), Mercedita Del Rosario, Eleni Venetsanakos, Elizabeth Ornelas, B.A. Appleton(Novartis (Switzerland)), Cynthia M. Shafer(Novartis (Switzerland)), Jiong Lan(Novartis (Switzerland)), Laura V. Doyle, Kenneth Crawford(Oklahoma Biological Survey), William F. Estacio
Cited by 0
Related Papers
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
|Nature Communications|2019|213
Evaluation of the North American Land Data Assimilation System over the southern Great Plains during the warm season
|Journal of Geophysical Research Atmospheres|2003|179
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
|Clinical Cancer Research|2014|111
Neonatal Development of the Stratum Corneum pH Gradient: Localization and Mechanisms Leading to Emergence of Optimal Barrier Function
|Journal of Investigative Dermatology|2003|97
Discovery of Potent and Selective RSK Inhibitors as Biological Probes
|Journal of Medicinal Chemistry|2015|84